Successful haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide in a child with X-linked chronic granulomatous disease: A first report in Asia

Asian Pac J Allergy Immunol. 2022 Sep;40(3):278-282. doi: 10.12932/AP-290419-0551.

Abstract

Background: HLA-matched hematopoietic stem cell transplantation (HSCT) is the curative treatment for chronic granulomatous disease (CGD).

Objective: To report a case of X-linked CGD with active infection successfully treated by haploidentical HSCT with post-transplant high dose cyclophosphamide (PTCY).

Methods: A 5-year-old Thai boy with CGD was undergone for haploidentical HSCT using PTCY with correction of the phagocytic function. He presented with Chromobacterium violaceum liver abscess at the age of 9 months and experienced recurrent perianal abscess and invasive pulmonary aspergillosis even receiving antimicrobial prophylaxis. PTCY was given on day 3 and 4, after CD34+ cells infusion.

Results: The peripheral blood-nucleated cell chimerism showed 100% on day 16 and remained 100%. Dihydrorhodamine (DHR) assay on day 108 and day 214 showed normal results. Currently at 22 months post HSCT, he does not receive antibiotic and anti-fungal prophylaxis.

Conclusions: Haploidentical HSCT with PTCY could be an effective treatment option for children with CGD.

Publication types

  • Case Reports

MeSH terms

  • Child
  • Child, Preschool
  • Cyclophosphamide / therapeutic use
  • Graft vs Host Disease* / drug therapy
  • Graft vs Host Disease* / prevention & control
  • Granulomatous Disease, Chronic* / complications
  • Granulomatous Disease, Chronic* / diagnosis
  • Granulomatous Disease, Chronic* / therapy
  • Hematopoietic Stem Cell Transplantation* / methods
  • Humans
  • Infant
  • Male
  • Transplantation Conditioning / methods

Substances

  • Cyclophosphamide